Drug Profile
Research programme: dioxygenase inhibitors - Lumos Pharma
Alternative Names: Ethyl pyruvate - Lumos Pharma; Indoleamine-2,3-dioxygenase (IDO) pathway inhibitors - Lumos Pharma; Tryptophan-2,3-dioxygenase inhibitors - Lumos PharmaLatest Information Update: 28 Apr 2021
Price :
$50
*
At a glance
- Originator Lankenau Institute for Medical Research
- Developer Genentech; Lankenau Institute for Medical Research; Lumos Pharma; NewLink Genetics Corporation
- Class Antineoplastics; Antivirals; Small molecules
- Mechanism of Action Indoleamine-pyrrole 2,3-dioxygenase inhibitors; Tryptophan oxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
- Discontinued Hepatitis C; HIV infections